Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. - Wikidata - awgldk - TriplyDB

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

http://www.wikidata.org/entity/Q36862505

about

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Expanding role of lenalidomide in hematologic malignancies International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Evolving treatment strategies in patients with high-risk acute myeloid leukemia.Acute myeloid leukemia in the elderly: therapeutic options and choice.The safety of treatment options for elderly people with acute myeloid leukemia.Acute Myeloid Leukemia in the Elderly Patient: New Strategies Treatment of Elderly Patients With Acute Myeloid Leukemia.Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.Expert insights into the contemporary management of older adults with acute myeloid leukemia.A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.The management and treatment of acute leukemias in the elderly population.Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report.Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis

P2860

Q26770391-25CF150C-694D-42AD-99C5-35D64CAC9D1B Q34342944-8C3BBC30-1726-48F7-9AED-AE42E675570C Q34350209-5D324E0E-D9BB-4843-AAAB-15D97CE9458E Q35592305-D2CA3818-6E03-4877-AD29-00AD95DFE009 Q35859212-FE5FD2FE-8B0D-4787-9E62-E2925583195B Q36522939-E474B550-031F-48F7-921D-A6869FEC04E9 Q36804633-D84597D7-489A-47CF-A77E-A6C9AC6513E8 Q36887700-B454A0C7-614A-4D56-89BC-A7E96592B6AA Q36934199-B0FFCCA3-AB95-465E-B754-D8A80BD8A8EC Q37074311-CF538BDD-B4E0-49AC-B0C0-D77CA03D5096 Q38104287-051791D3-BCCD-40AB-B94A-CE7680C4C2D8 Q38161965-02F9314C-D60C-42E0-9ACF-3CBDADC2EC50 Q38179026-94B64DCB-6FF3-49C4-89C3-D22261ADBD9F Q38675781-F23C47E0-C022-4EF7-96EE-935D906AEAEC Q38760822-AD9CBC2A-62FF-4820-8CE8-21A7A08A8938 Q38835119-FF9892C0-EFDB-4A59-9F8B-26E361F522D6 Q39112940-1F18433E-330D-4DC7-BEFE-97A0CDABBC05 Q40139200-1C0FD425-EE11-4B95-BEAD-51DF7A1F6268 Q41080080-79CD0CB1-3530-4897-852B-20E90DFAF738 Q44898238-B00B83BE-E377-4252-AEA8-589FAF5C1BDC Q45072417-BCD8C93D-B5DF-4F64-9065-4FB01FB0174B Q46990862-E7DAA6F9-EC0A-44D8-B8B0-9288A506EA12 Q47665959-3A473C73-90AE-452A-A965-158550C2C16B Q49987424-54675C96-9F0B-4957-8B1E-F991C19E61DA Q51111341-0667A5C3-F35D-4C64-BA42-EA2F00950420 Q52604951-434EB7C5-B4BD-4DCD-A36E-209044D085E4 Q54265269-E4AAE830-B61D-4502-A39B-5FD6137A8A9A Q56974946-21D60A1E-CADB-4046-A9E5-1B053F3E6BCA Q57073560-9731DCB6-872A-4032-8900-0698BA14E906

P2860

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

http://www.wikidata.org/entity/Q36862505

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Sequential azacitidine plus le ...... reated acute myeloid leukemia.

@en

type

label

Sequential azacitidine plus le ...... reated acute myeloid leukemia.

@en

prefLabel

Sequential azacitidine plus le ...... reated acute myeloid leukemia.

@en

P1433

Q36862505-B3D7790B-824F-466D-AEB8-3264D502EF5B

P1476

Q36862505-A502A8B0-7FF7-463C-B845-F57C046E7DD4

P2093

Q36862505-2A41E157-E6E5-4808-8403-6FDC9D906366

Q36862505-4E80BEEE-CBED-465D-821B-E20968F4DF14

Q36862505-5D003349-5FBB-4D30-8197-E55C662774BE

Q36862505-63E574DF-C80B-4E85-9AD3-8484253112C8

Q36862505-7ADD580F-FA3F-425F-A0C0-52F434B140D4

Q36862505-B6EB18BF-975F-4542-BD76-259A477ABCDD

Q36862505-BB3F8FDB-741B-4094-B45D-84E03C991149

Q36862505-C434AA09-2E25-43B8-93F9-81D228ED0EA0

Q36862505-E78AE9A2-E8E5-45C9-909B-B8646F33DA00

Q36862505-E9663E07-43EA-4406-9258-9E2EF023073D

P2860

Q36862505-072FCCCD-23D5-4B18-A15C-B26F38FB7A79

Q36862505-25DA7747-369A-41E9-897E-0652417C160C

Q36862505-2CC8748B-55FC-4658-A94A-CE7A668EA605

Q36862505-2F99C803-5AE5-4549-BA9E-9B0B782FC353

Q36862505-396A2C42-C0E6-41E1-839F-FECC33E29388

Q36862505-3B920854-0443-450A-A333-217EAE107558

Q36862505-560532D8-065B-4E74-ADC9-BD8B797C7566

Q36862505-56C99A81-63FC-4107-8769-76E5B7C9A5B1

Q36862505-7BAAAB2F-1482-48DB-8701-3CED6134997C

Q36862505-7D61536A-DC80-4D54-A6EA-14AE8D942BD6

P304

Q36862505-90BA888A-B633-4229-83B6-947CDEA862EE

P31

Q36862505-F0E78EBB-5F0C-43FB-88DA-2AEB054AD384

P356

Q36862505-49BF53D9-D645-4AB3-9C7C-679CBCEB5D9F

P433

Q36862505-CCA62B4C-3A39-4B72-815A-F6AE70473831

P478

Q36862505-0E4F13AC-C584-4B1D-A338-7117D5DF3C7B

P577

Q36862505-6E1C36BC-8962-4FD0-9A8A-98D1C0F3C810

P5875

Q36862505-7A6D4590-2E6B-476D-B209-BE4F80D3062A

P698

Q36862505-FBF770D8-B512-49BF-9762-4A529B910172

P921

Q36862505-F8A61E27-FB3C-4E81-B28D-46CE27037379

P932

Q36862505-EBE19CEC-94FA-4F13-B930-5063E471B2A0

P356

HAEMATOL.2012.076414

P1433

P1476

Sequential azacitidine plus le ...... reated acute myeloid leukemia.

@en

P2093

Beverly S Mitchell

http://www.w3.org/2001/XMLSchema#string

Bing Zhang

http://www.w3.org/2001/XMLSchema#string

Bruno C Medeiros

http://www.w3.org/2001/XMLSchema#string

Caroline Berube

http://www.w3.org/2001/XMLSchema#string

Daniel A Pollyea

http://www.w3.org/2001/XMLSchema#string

James Zehnder

http://www.w3.org/2001/XMLSchema#string

Jason R Gotlib

http://www.w3.org/2001/XMLSchema#string

Leonel Gallegos

http://www.w3.org/2001/XMLSchema#string

Michaela Liedtke

http://www.w3.org/2001/XMLSchema#string

Omar Abdel-Wahab

http://www.w3.org/2001/XMLSchema#string

P2860

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Gene silencing in cancer in association with promoter hypermethylation

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

P304

591-596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2012.076414

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233931033

http://www.w3.org/2001/XMLSchema#string

P698

23242596

http://www.w3.org/2001/XMLSchema#string

P921

P932

3659990

http://www.w3.org/2001/XMLSchema#string